For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
The price of Avidity Biosciences Inc (NASDAQ: RNA) closed at $36.88 in the last session, up 2.59% from day before closing price of $35.95. In other words, the price has increased by $2.59 from its previous closing price. On the day, 3.91 million shares were traded. RNA stock price reached its highest trading level at $38.9999 during the session, while it also had its lowest trading level at $36.785.
Ratios:
We take a closer look at RNA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 16.91 and its Current Ratio is at 16.91. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On June 24, 2025, Bernstein started tracking the stock assigning a Outperform rating and target price of $50.
On June 17, 2025, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $55.Wolfe Research initiated its Outperform rating on June 17, 2025, with a $55 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 17 ’25 when Gallagher Kathleen P. sold 911 shares for $30.24 per share. The transaction valued at 27,549 led to the insider holds 50,392 shares of the business.
KATHLEEN GALLAGHER bought 911 shares of RNA for $27,148 on Jun 17 ’25. On Jun 11 ’25, another insider, Flanagan W. Michael, who serves as the Chief Scientific Officer of the company, sold 20,000 shares for $32.88 each. As a result, the insider received 657,694 and left with 80,195 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RNA now has a Market Capitalization of 4444777984 and an Enterprise Value of 3071551744. For the stock, the TTM Price-to-Sale (P/S) ratio is 497.81 while its Price-to-Book (P/B) ratio in mrq is 3.34. Its current Enterprise Value per Revenue stands at 344.074 whereas that against EBITDA is -7.137.
Stock Price History:
The Beta on a monthly basis for RNA is 0.95, which has changed by -0.17253757 over the last 52 weeks, in comparison to a change of 0.16821623 over the same period for the S&P500. Over the past 52 weeks, RNA has reached a high of $56.00, while it has fallen to a 52-week low of $21.51. The 50-Day Moving Average of the stock is 15.88%, while the 200-Day Moving Average is calculated to be 9.28%.
Shares Statistics:
According to the various share statistics, RNA traded on average about 1.78M shares per day over the past 3-months and 2910070 shares per day over the past 10 days. A total of 120.51M shares are outstanding, with a floating share count of 109.72M. Insiders hold about 8.98% of the company’s shares, while institutions hold 107.53% stake in the company. Shares short for RNA as of 1752537600 were 16259911 with a Short Ratio of 9.12, compared to 1749772800 on 16344285. Therefore, it implies a Short% of Shares Outstanding of 16259911 and a Short% of Float of 13.62.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
